Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Public ClinicalTrials.gov record NCT04291105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)
Study identification
- NCT ID
- NCT04291105
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2020
- Primary completion
- Sep 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Jul 7, 2026
2020 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Saint John's Health Center - John Wayne Cancer Institute (JWCI) | Santa Monica | California | 90404 | — |
| Yale University | New Haven | Connecticut | 06520-8032 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Billings Clinic Montana Cancer Consortium | Billings | Montana | 59101 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04291105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04291105 live on ClinicalTrials.gov.